Modern approach to combination therapy in patients with pelvic inflammatory diseases

Abstract

Objective. The aim of the study was to compare the efficiency of complex therapy of pelvic inflammatory diseases (PID) in patients using the drug Longidaza® and the effectiveness of therapy without the use of this drug.

Materials and methods. 150 patients of reproductive age with PID. All women underwent basic therapy. The complex treatment of group 1 included the additional drug Longidaza® in vaginal suppositories 3000 IU with the general course of 20 injections once every three days. The patients were observed for 60 days. The effectiveness of therapy was determined by the dynamics of diagnostic criteria (clinical and laboratory).

Results. During the follow-up period, among patients receiving complex therapy with Longidaza® relief of pain syndrome in the lower abdomen was observed much faster, and only 14 (18,5 %) women of group 1 continued to fill it after 2 months of treatment, where as in group 2 – 60 (81,1 %) patients (p < 0,001). Reduction of pain in palpation and cervical traction in patients of the main group was recorded in all (100 %) patients, while in the group of basic therapy this symptom continued to be observed in 23 % of women (p < 0.001). The dynamics of decrease in the share of patients with increased uterine size in group 1 was 14.9 % and in group 2 – only 8.4 % (p < 0.001). In the experimental group, during the 2-month follow-up period, there was observed an increase in the number of patients with a normal number of leukocytes in the vaginal smear by 13 %, while in the second group this parameter increased by only 3 % to the initial value.

Conclusions. The results of the research allow indicating the efficiency of treatment of PID when using the drug Longidaza®.

Keywords

pelvic inflammatory diseases (PID) / therapy / Longidaza® / pain syndrome / patients

References

[1] Sexually Transmitted Diseases Treatment Guidelines, СDC. MMWR. June 5, 2015; 64 (3): 137.

[2] Sexually Transmitted Diseases Treatment Guidelines, СDC. MMWR 2015; 64 (3): 137.

[3] Kobaidze E.G., Padrul M.M. Impaired function of the endometrium in chronic inflammation of the uterus. Permskij medicinskij zhurnal 2014; 31 (5): 92–101 (in Russian).

[4] Кобаидзе Е.Г., Падруль М.М. Нарушение функции эндометрия при хронических воспалениях матки. Пермский медицинский журнал 2014; 31 (5): 92–101.

[5] Kubanova A.A, Lesnaya I.N., Kubanov A.A., Melekhina L.E., Kaspirovich M.A. Analysis of the epidemiological situation and the dynamics of the incidence of sexually transmitted infections and dermatoses in the Russian Federation. Vestnik dermatologii i venerologii 2010; 5: 4–21 (in Russian).

[6] Кубанова А.А. Лесная И.Н., Кубанов A.A., Мелехина Л.Е., Каспирович М.А. Анализ эпидемиологической ситуации и динамика заболеваемости инфекциями, передаваемыми половым путем, и дерматозами на территории Российской Федерации. Вестник дерматологии и венерологии 2010; 5: 4–21.

[7] Sweet R.L. Pelvic Inflammatory Disease: Current Concepts of Diagnosis and Management. Curr Infect Dis Rep 2012; 14: 194–203.

[8] Olina A.A., Sadykova G.K., Meteleva T.A. Analysis of demographic processes in the Perm Region. Permskij medicinskij zhurnal 2018; 35 (3): 67–73 (in Russian).

[9] Олина А.А., Садыкова Г.К., Метелева Т.А. Анализ демографических процессов в Пермском крае. Пермский медицинский журнал 2018; 35(3): 67–73.

[10] Prilepskaya V.N., Bebneva T.N. The effectiveness of the immunomodulator Galavit in the treatment of inflammatory diseases of the pelvic organs. Russkij medicinskij zhurnal 2013; 1: 31–38 (in Russian).

[11] Прилепская В.Н., Бебнева Т.Н. Эффективность иммуномодулятора Галавита в лечении воспалительных заболеваний органов малого таза. Русский медицинский журнал 2013; 1: 31–38.

[12] Serov V.N., Tverdikova M.A., Veresova A.A. Immunomodulators in the complex therapy of inflammatory diseases of the pelvic organs. Russkij medicinskij zhurnal 2011; 20: 1218–1223 (in Russian).

[13] Серов В.Н., Твердикова М.А., Вересова А.А. Иммуномодуляторы в комплексной терапии воспалительных заболеваний органов малого таза. Русский медицинский журнал 2011; 20: 1218–1223.

[14] Kurbanova D.F. Inflammatory diseases of the uterus appendages. M.: Medicine 2007; 160 (in Russian).

[15] Курбанова Д.Ф. Воспалительные заболевания придатков матки М.: Медицина 2007; 160.

[16] Baymuradova S. M. Pathogenesis, principles of diagnosis, prevention and therapy of fetal loss syndrome caused by acquired and genetic defects of hemostasis: diss. … doctor of Medical Sciences. Moscow 2007; 396 (in Russian).

[17] Баймурадова С.М. Патогенез, принципы диагностики, профилактики и терапии синдрома потери плода, обусловленного приобретенными и генетическими дефектами гемостаза: автореф. дис. ... д-ра мед. наук М. 2007; 396.

[18] Tirskaya Y.I., Rudakova E.B. Schakina I.A., Tsygankova O.Y. The role of cervicitis in obstetric and gynecological pathology. Lechashhij vrach 2009; 10: 63–66 (in Russian).

[19] Тирская Ю.И., Рудакова Е.Б., Шакина И.А., Цыганкова О.Ю. Роль цервицитов в акушерско-гинекологической патологии. Лечащий врач 2009; 10: 63–66.

[20] Tatarchuk T.F., Efimenko O.A. The role of hyperprolactinemia in the formation and realization of reproductive function. Mezhdunarodnyj jendokrinologicheskij zhurnal 2010; 3 (27) (in Russian).

[21] Татарчук Т.Ф., Ефименко О.А. Роль гиперпролактинемии в становлении и реализации репродуктивной функции. Международный эндокринологический журнал 2010; 3 (27).

[22] Barinov S.V., Pisklakov A.V., Shakhoval V.S., Pavlenko N.I. Chronic pelvic pain syndrome in girls. Medicinskaja nauka i obrazovanie Urala 2012; 13 (71): 36–39 (in Russian).

[23] Баринов С.В., Писклаков А.В., Шаховал В.С., Павленко Н.И. Хронический тазовый болевой синдром у девочек. Медицинская наука и образование Урала 2012; 13 (71): 36–39.

[24] Krasnopolsky V.I., Buyanova S.N., Shchukina N.A. Purulent inflammatory diseases of the uterine appendages. Moscow: MEDpress-Inform 2006; 296 (in Russian).

[25] Краснопольский В.И., Буянова С.Н., Щукина Н.А. Гнойные воспалительные заболевания придатков матки М.: МЕДпресс-информ 2006; 296.

[26] Bugg C.W., Taira T., Zaurova M. Pelvic inflammatory disease: diagnosis and treatment in the emergency department [digest]. Emerg Med Pract 2016; 1 (12, Suppl. Points & Pearls): 1–2 (in Russian).

[27] Bugg C.W., Taira T., Zaurova M. Pelvic inflammatory disease: diagnosis and treatment in the emergency department [digest]. Emerg Med Pract 2016; 1 (12, Suppl. Points & Pearls): 1–2.

[28] Olina A.A. Epidemiological and microbiological aspects of non-specific infectious diseases of the vagina. Ural'skij medicinskij zhurnal 2008; 8 (48): 160–163 (in Russian).

[29] Олина А.А. Эпидемиологические и микробиологические аспекты неспецифических инфекционных заболеваний влагалища. Уральский медицинский журнал 2008; 8 (48): 160–163.

[30] Padrul M.M., Olina A.A., Pirozhnikova N.M., Padrul V.M. Immunotherapy of sexually transmitted infections. Training manual. Perm 2006; 81 (in Russian).

[31] Падруль М.М., Олина А.А., Пирожникова Н.М., Падруль В.М. Иммунотерапия инфекций, передаваемых половым путем: учебное пособие. Пермь 2006; 81.

[32] Instructions for the medical use of the drug Longidase vaginal and rectal suppositories. LSR-002940/07. 2016 (in Russian).

[33] Инструкция по медицинскому применению лекарственного препарата Лонгидаза суппозитории вагинальные и ректальные. ЛСР-002940/07 2016.

[34] Nekrasov A.V., Ivanova A.S. Longidase – a modern approach in the treatment of diseases accompanied by connective tissue hyperplasia. Signatura 2006; 1: 43–52 (in Russian).

[35] Некрасов А.В., Иванова А.С. Лонгидаза® – современный подход в лечении заболеваний, сопровождающихся гиперплазией соединительной ткани. Signatura 2006; 1: 43–52.

RIGHTS & PERMISSIONS

Khasanova V.V., Kukarskaya I.I., Shevlyukova T.P., Kukarskaya E.Y.